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Abstract
Background: Involvement of nitric oxide (NO) in the pathophysiology of human African trypanosomiasis (HAT) was
analyzed in a HAT animal model (rat infected with Trypanosoma brucei brucei). With this model, it was previously reported
that trypanosomes were capable of limiting trypanocidal properties carried by NO by decreasing its blood concentration. It
was also observed that brain NO concentration, contrary to blood, increases throughout the infection process. The present
approach analyses the brain impairments occurring in the regulations exerted by arginase and N
G,N
G–dimethylarginine
dimethylaminohydrolase (DDAH) on NO Synthases (NOS). In this respect: (i) cerebral enzymatic activities, mRNA and protein
expression of arginase and DDAH were determined; (ii) immunohistochemical distribution and morphometric parameters of
cells expressing DDAH-1 and DDAH-2 isoforms were examined within the diencephalon; (iii) amino acid profiles relating to
NOS/arginase/DDAH pathways were established.
Methodology/Principal Findings: Arginase and DDAH activities together with mRNA (RT-PCR) and protein (western-blot)
expressions were determined in diencephalic brain structures of healthy or infected rats at various days post-infection (D5,
D10, D16, D22). While arginase activity remained constant, that of DDAH increased at D10 (+65%) and D16 (+51%) in
agreement with western-blot and amino acids data (liquid chromatography tandem-mass spectrometry). Only DDAH-2
isoform appeared to be up-regulated at the transcriptional level throughout the infection process. Immunohistochemical
staining further revealed that DDAH-1 and DDAH-2 are contained within interneurons and neurons, respectively.
Conclusion/Significance: In the brain of infected animals, the lack of change observed in arginase activity indicates that
polyamine production is not enhanced. Increases in DDAH-2 isoform may contribute to the overproduction of NO. These
changes are at variance with those reported in the periphery. As a whole, the above processes may ensure additive
protection against trypanosome entry into the brain, i.e., maintenance of NO trypanocidal pressure and limitation of
polyamine production, necessary for trypanosome growth.
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Introduction
Human African trypanosomiasis (HAT), or sleeping sickness, is
caused by the protozoan parasites Trypanosoma brucei (T. b.)
gambiense or T. b. rhodesiense. These parasites, transmitted by the bite
of an infected tse tse fly, cause a two-stage disease. The early
hemolymphatic stage 1 corresponds to the proliferation of the
parasite in the blood and lymph. This stage is followed by the
meningoencephalitic stage 2 during which the parasites invade the
central nervous system (CNS) [1]. If untreated, the disease evolves
towards death in a deep cachectic condition.
Nitric oxide (NO), a gaseous signaling molecule that acts as a
messenger in the immune and nervous systems, has been involved
in the physiopathological processes that occur in the rat model of
HAT [2]. NO is a highly reactive molecule possessing a very short
half-life (,0.5 second) and is synthesized from the amino acid L-
arginine by three major isoforms of NO Synthase (NOS): the
neuronal NOS (nNOS, type 1), the inducible NOS (iNOS, type 2)
and the endothelial NOS (eNOS, type 3) [3]. The production of
NO by iNOS takes place during inflammatory and infectious
situations. Accordingly, it is a key element in counteracting the
proliferation of trypanosomes through its cytotoxic properties
[4,5]. The biological availability of NO is achieved directly by the
activity of the NOS enzymes. These enzymes are further
submitted to a complex regulation involving arginase and N
G,
N
G-dimethylarginine dimethylaminohydrolase (DDAH) enzymes
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e16891(Fig. 1). Arginase, in catalyzing the last step of the urea cycle, leads
to the production of L-ornithine, a synthesis precursor of L-
proline, L-glutamate, L-glutamine, c-aminobutyric acid (GABA)
and polyamines (Fig. 1). Arginase exists in two isoforms: (i)
arginase-1 (liver isoform) is strongly expressed in the cytosol of liver
cells; (ii) while arginase-2 (extra-liver isoform, predominant in
kidney) is localized into the mitochondrial membrane of cells. In
the brain, arginase-1 and, to a lesser extent, arginase-2 have been
identified in neurons but not in glial cells.
Arginase activity is particularly high in brain regions with strong
nNOS expression [6]. Arginase may contribute to reduce NOS
activity, due to the use of the common substrate, L-arginine.
Figure 1. Simplified scheme of L-arginine pathways in mammalian host cells. L-arginine is a crossroad for multiple pathways since it is the
common substrate of arginase and NOS that catalyzes the production of L-ornithine, L-citrulline and NO, respectively. ADMA, a product of the
proteolysis of methylated proteins by PRMT-1, is a potent inhibitor of NOS. Its concentration is regulated by DDAH that catalyzes the production of L-
citrulline and dimethylamine. L-ornithine and L-glutamate serve as precursors of polyamines and glutathione. These two metabolites will be further
utilized by the trypanosomes for the synthesis of trypanothione, an essential element protecting the parasites from free radicals. Abbreviations: NO,
nitric oxide; NOS, nitric oxide synthase; ADMA, asymmetric dimethylarginine; DDAH, N
G,N
G-dimethylarginine dimethylaminohydrolase; PRMT-1,
Protein arginine N-methyltransferase 1; GABA, c-aminobutyric acid.
doi:10.1371/journal.pone.0016891.g001
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the intermediate product of the reaction catalyzed by NOS [7].
Another potent way regulating NO synthesis is mediated by
DDAH. This enzyme catalyzes the hydrolysis of asymmetric
dimethylarginine (ADMA) to dimethylamine and L-citrulline.
ADMA is a product of the catabolism of arginine-methylated
proteins by protein arginine N-methyltransferase 1 (PRMT-1) [8]
(Fig. 1). As for arginase, two isoforms of DDAH have been
described, DDAH-1 and DDAH-2. It is reported that DDAH-1 is
typically located in nNOS-containing tissues, whereas DDAH-2
predominates in iNOS-expressing tissues and in vascularized areas
where eNOS is present [9]. All NOS isoforms can be inhibited by
ADMA, the substrate of DDAH. Under certain conditions, the S-
nitrosylation of DDAH by NO may lead to a strong decrease in its
activity, leading subsequently to an accumulation of ADMA and
NOS inhibition. This feedback mechanism may thus contribute to
the regulation of NO production [10].
In a recent study conducted in the rat infected with T. b. brucei,
an experimental model of HAT, the production of NO was
analyzed both in the brain (hypothalamus/thalamus) and the
periphery (blood) [2]. Changes occurring in NO production were
dependent on iNOS activity. In the periphery, two main
observations were recorded: (i) a marked decrease in blood NO
production which likely limits the NO trypanocidal activity; and
(ii) an increased activity of arginase favouring the synthesis of
polyamines necessary for trypanosome growth [11]. In the brain,
on the contrary, an increase in NO production occurred due to an
enhanced iNOS activity in neurons and glial cells. Consequently,
the iNOS activation observed in brain cells was primarily
considered as a marker of deleterious inflammatory processes.
To date, the brain mechanisms of this infection are part of the
most severe aspects of the disease and remain unknown. The
present work, an extension of the above investigations [2], focused
on the relative role of arginase and DDAH in the brain during the
different stages of T. b. brucei infection. Measures were performed
throughout the time course of the infection in the rat model infected
with T. b. brucei to assess (i) the cerebral changes occurring in the
enzymatic activities, mRNA and protein expression of arginase and
DDAH; (ii) the determination of the immunohistochemical
distribution and the morphometric parameters of the cells
expressing the isoforms of DDAH (DDAH-1 and DDAH-2) within
the diencephalon;and (iii) the changes occurringin the profile of the
amino acids related to the NOS/arginase/DDAH pathways.
Materials and Methods
Ethics statement
All animals were handled in strict accordance with good animal
practice in compliance with the relevant decree of the French
Agriculture Ministry (Nu: 03-505). Animal procedure was
approved by Departmental Direction of Veterinary Services of
Rho ˆne-Alpes.
Animals and infection
Male Wistar rats (Janvier breeding, Le Genest Saint Isle,
France) weighing 200–220 g, were kept under standard laboratory
conditions: 12 h/12 h light/dark cycle, ambient temperature of 21
to 22uC, food and water ad libitum. After one week of adaptation,
two groups of animals (control, n=24; infected, n=24) were
constituted. The animals were infected with the AnTat 1.1 E clone
of T. b. brucei (Institute of Tropical Medicine, Antwerp, Belgium).
Before infection, the mobility and viability of trypanosomes were
controlled under microscope. The intraperitoneal (i.p.) injection of
3,600 parasites defined the initial day (D0) of the experimental
session. In parallel, control animals received an i.p. injection of the
same volume of physiological saline solution.
In the infected rats (HAT experimental model), body weight
was measured and blood parasites counted every two days as
previously described [2]. Cerebrospinal fluid (CSF) samples were
obtained from cisterna magna puncture achieved under chloral
hydrate anesthesia (400 mg/kg). Parasite counts in CSF samples
were performed every four days after infection (from D10 to D22).
The biological signs characterizing the entry into the neurological
state of the disease appeared, as previously described [2], from D5
to D10 post-infection. At this time, however, the parasites were not
yet observed in the CSF (hemolymphatic stage 1). From D10 to
D22, while the body weight gain continue to declines, trypano-
somes were observed in the CSF (neurological stage 2). The
animals were sacrificed by decapitation at days D5, D10, D16 and
D22 post-infection.
Dissection and protein extracts from brain tissue
In order to obtain protein extracts from cerebral tissues, the
brain of each animal was quickly removed, briefly rinsed in ice-
cold Tris-EDTA buffer (50 mM, pH 7.4), and dissected to collect
the diencephalic (hypothalamus/thalamus) structure. Protein
extracts from brain tissue were obtained as previously described
[2] and protein concentrations were determined in supernatant
fractions using Bradford’s method [12].
Plasma samples
Blood samples were obtained from direct puncture of the heart
with a heparinized syringe and centrifuged at 2,400 g (4uC,
10 min). Then, plasma supernatant was removed and samples
kept at 280uC until use.
Arginase and DDAH activity in brain tissue
Measurement of arginase activity. Arginase activity was
determined by analyzing the conversion of L-arginine to urea with
the colorimetric method described by Liu et al. [13]. Briefly, for
the enzyme activation, 15 mL of a solution containing 10 mM
MnCl2 in 50 mM Tris-HCl (pH 7.5) were added to 15 mL of each
diencephalic protein extract (about 75 mg of proteins). The
mixture was incubated at 55uC for 10 min. Then, 30 mL of the
substrate, 0.2 M L-arginine, were added and the new mixture
incubated for 5 min at 37uC. The enzymatic reaction was stopped
by adding 40 mL of 20% H2SO4. To quantify urea formation,
2.5 mL of a 20% H2SO4 solution containing 0.4% w/v antipyrin,
0.005% w/v iron (III)-sulfate hydrate and 2.5 mL of a 5% acetic
acid solution containing 0.5 w/v diacethyl monoxim were added.
After incubation at 100uC for 15 min, the absorbance of the
colored product was measured at 450 nm. All assays were carried
out in duplicates. The blank assay was performed in the same way,
except that the enzymatic reaction was stopped with the acidic
solution immediately after addition of the substrate to each
diencephalic protein sample. The specific activity corresponding to
nanomoles of urea formed per min and per mg of proteins (nmol/
min/mg) was expressed as % of the values obtained in the non-
infected condition. The arginase activity obtained from samples of
rat liver was used as positive control.
Measurement of DDAH activity. DDAH activity was
measured by analyzing the conversion of ADMA to L-citrulline.
After the addition of 225 mL of 5 mM ADMA in 100 mM
phosphate buffer (pH 6.5) to 25 mL of each diencephalic protein
extract (about 125 mg of proteins), the mixture was incubated at
37uC for two hours. The reaction was stopped by the addition of
250 mL of 10% tricloroacetic acid (ice-cold). After centrifugation
(10 min at 3,000 g), 250 ml of a 20% H2SO4 solution containing
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containing 0.8% w/v diacethyl monoxim, were added to each
supernatant sample (about 490 mL) containing L-citrulline. The
mixtures were then incubated at 100uC for 12 min before
measuring the absorbance at 466 nm as described by Prescott
and Jones [14]. All assays were carried out in duplicate. The blank
assay was performed in the same way, except that the enzymatic
reaction was immediately stopped (by the ice-cold tricloroacetic
acid) just after addition of the buffered substrate solution to each
diencephalic protein sample. The specific activities (picomoles of
citrulline formed per min and per mg of protein (pmol/min/mg))
were expressed in % of the values obtained in the non-infected
condition. The DDAH activity obtained from samples of rat
kidney was used as positive control.
Western-blotting
Forty mg of the total protein extract obtained from diencephalic
samples was loaded and separated on NuPAGEH NovexH 10%
Bis-Tris gels with MOPS running buffer (Invitrogen-Life Tech-
nologies, Cergy-Pontoise, France). Protein transfers to nitrocellu-
lose membranes were performed using the iBlot
TM DryBlotting
device (Invitrogen) and iBlot
TM Transfer stacks (program P3 for
7 min). After transfer, membranes were first saturated for one
hour at room temperature in buffer A (Tris 50 mM pH 7.5, NaCl
166 mM, Tween 0.2%) containing 5% of non fat dry milk,
followed by an incubation with the rabbit polyclonal anti-DDAH-
1 (1/500, Orbigen, San Diego, USA), rabbit polyclonal anti-
DDAH-2 (H-85 1/200, Santa Cruz Biotechnology, California,
USA), rabbit polyclonal anti-arginase-1 (H-52, 1/200, Santa Cruz
Biotechnology), rabbit polyclonal anti-arginase-2 (H-64, 1/200,
Santa Cruz Biotechnology) or mouse anti-b actin antibody (1/
1000, Santa Cruz Biotechnology) for 6 hours in buffer A
containing 2.5% of non fat dry milk. After three washings in
buffer A, membranes were incubated during one hour with
corresponding biotinylated secondary antibody, goat anti-rabbit
(1/2000, Vector Labs, ABCYS, Paris, France), or goat-anti mouse
(1/1000, Vector Labs) in buffer A containing 2.5% non fat dry
milk, washed again in buffer A, then incubated for two hours with
avidin-peroxidase (1/1000, Vectastain kit, Vector Labs) in buffer
A. Blots were then washed three times and the conjugates were
visualized by enhanced chemiluminescence (ECL) (Super Signal
West Pico, Pierce, Thermo Scientific, and Courtabeuf, France).
The ECL signals were acquired with ChemidocXRS (BioRad,
Marnes-la-Coquette, France) and quantified with Quantity One
software (BioRad). Blots of anti-b actin were used as internal
standard and samples of kidney and liver as positive controls.
Quantification of the blots was performed using a BioRad
ChemiDoc software. Mean values determined are given for
control and experimental groups at different days post infection
(D5, D10, D16 and D22).
Real-time RT-PCR
As previously described [15], total RNA was prepared from
diencephalic brain samples using a RNA-plus solution (Q-Biogen,
Illkirch, France). For each gene, the sequence of the primer pairs
and the annealing temperature are given in Table 1. Results were
normalized to 18S rRNA as endogenous control and expressed in
percent of the corresponding values of the non-infected condition.
Table 2. Specific parameters used for identification of amino acid in MS/MS positive ion mode.
Monitored transition
(m/z) CV (V) CE (eV) AA* RT (min)
Derivatized (butylated) AA
L-citrulline 232.113 20 18 L-pro* 3.11
L-ornthine 189.70 12 18 L-orn* 1.10
ADMA 259.214 28 14 L-arg* 2.16
Underivatized AA
L-arginine 175.70 20 32 L-arg* 12.71
L-proline 116.70 20 30 L-pro* 2.38
L-glutamate 148.84 15 24 L-glu* 2.07
L-glutamine 147.84 20 24 L-gln* 2.02
GABA 104.87 20 14 L-lys* 9.16
AA: Amino acid.
CV, CE correspond to the cone voltage (in V), and collision energy (in eV), respectively.
AA* corresponds to the stable labelled amino acid (AA) chosen as internal standard for the quantification.
RT corresponds to the time of retention (in min) of each analyte under selected chromatographic conditions.
ADMA: asymmetric dimethylarginine. GABA: c-aminobutyric acid.
doi:10.1371/journal.pone.0016891.t002
Table 1. Real-time PCR analysis: sequence of the
oligonucleotide pairs, annealing temperature (Ta) and
product size.
Genes Primer pairs Ta (6C)
Product size
(bp)
DDAH-1 ACTCACTCCAGCCTCTGTGT
TCCACGTTCTCAGGACTCTC
57 153
DDAH-2 AACTGAGGCAACGACTAGGT
GATTAGAGCCGTGTCTCCTT
58 113
ARG-1 GGCAGTGCCGTTGACCTTGT
AGCAGCGTTGGCCTGGTTCT
59 158
ARG-2 TGTCGGCTCTGGATCTTGTT
AATGTGTCCGCCTTCTCTTG
57 131
18S TAGAGGGACAAGTGGCGTTC
CGCTGAGCCAGTCAGTGTAG
64 100
doi:10.1371/journal.pone.0016891.t001
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Animal perfusion, brain fixation and cutting were achieved as
previously described [2]. Saturation of the non specific binding
sites of the antibody was performed by incubating the brain
sections (25 mm thick) for 90 min in a phosphate buffered saline
solution (PBS; 50 mM, pH 7.4) containing 1% of bovine serum
albumin (BSA). Rabbit polyclonal anti-DDAH-1 antibody (1/500,
Orbigen, San Diego, USA) and goat polyclonal anti-DDAH-2
antibody (1/500, Abcam, Paris, France) were used as primary
antibody (2624 h at 4uC). Biotinylated goat anti-rabbit (1/500,
Vector Labs, ABCYS, Paris, France) and rabbit anti-goat (1/500,
Vector Labs) were used as secondary antibody (12 h at 4uC).
Three infected or un-infected rats were used for DDAH-1 and
DDAH-2 immunohistochemistry. Rat kidney, expressing predom-
inantly DDAH isoforms, was used as specific controls for the
different antibodies employed.
Morphometric analysis of DDAH-1 and DDAH-2
expressing cells
The analysis was achieved on the ventral and posterior parts of
the thalamus, an area where DDAH-1 and DDAH-2 immuno-
reactivity had been observed. The morphometric parameters
employed were as follows: (1) Soma area (mm
2); (2) Soma perimeter
(mm); (3) Soma form factor (FF*=4p6Area/Perimeter, FF* values
equaled 1.0 for a perfect circle and ,1.0 for all ellipses).
Measures were taken from 268 elements, i.e., 134 cells for each
DDAH brain section isoform (DDAH-1 or DDAH-2). The
external border of the soma was delimited by way of a computer
mouse, then, the area of the soma, perimeter and form factor were
automatically calculated by the Mercator software which was
related to the Axioscope2 plus microscope and the QIMAGING
camera.
Amino acids (AA) assay by liquid chromatography
tandem-mass spectrometry (LC-MS/MS)
L-Arginine, L-glutamate, L-glutamine, L-proline and GABA
were quantified in diencephalic brain structures as underivatized
AA by the LC-MS/MS method previously described by Piraud et
al. [16]. Only L-Arginine, L-glutamate and L-glutamine were
quantified in blood samples by the same method. L-Citrulline, L-
ornithine (in brain) and ADMA (in blood), were quantified as butyl
esters derivatives in order to improve the detection limit. The
method used is adapted from Schwedhelm et al. [17] with some
slight modifications of the chromatographic gradient and the
internal standard.
Derivatized AA assay
Standards and samples preparation. Fifty mLo f
calibration standard solutions (L-citrulline, L-ornithine or
ADMA in increasing quantities: 0, 0.5, 1, 2, 5, 10, and 20 mM
each), or 50 mL of brains extracts or 50 mL of plasma samples,
were mixed with 20 mL of internal standard solution at 14 mML -
[
2H] proline (Pro*), L-[
2H] ornithine (Orn*) and L-[
2H] arginine
(Arg*) (Cambridge Isotope Laboratories, Andover, USA). Protein
and lipid precipitation was performed by adding 400 mLo f
ethanol and 400 mL hexane to all samples. The samples were then
mixed for 2 min and stored for 10 min at room temperature.
Afterwards, the supernatant was eliminated and the residual phase
again precipitated by 400 mL of hexane. After centrifugation
during 5 min at 17,500 g, dried supernatant were derivatized by
butylation using 200 mL of 3N HCl in butanol (Interchim,
Montluc ¸on, France), followed by evaporation according to
Schwedhelm et al. [17]. Finally, dried samples were
reconstituted in 50 mL of the mobile phase (formic acid/
methanol, 1 mL/1 L) and fractions of 5 mL of brain extracts or
20 mL of plasma were injected into the LC apparatus.
LC and gradient conditions. The derivatized AA separation
was achieved using reversed-phase liquid chromatography (Waters
Alliance 2795 LC set-up, Waters Corporation, Beverly, MA, USA)
witha Variananalytical column (2.0650 mm)packedwitha Polaris
C18-Ether (3 mm Bead size, Varian, Courtaboeuf France). Before
use, the column was rinsed with methanol during one hour at a flow
rate of 0.1 mL/min, then, overnight, with methanol/water (50/50,
v/v). The chromatography was performed at 25uC with a flow rate
of 0.2 mL/min. The gradient started with 10% mobile phase A
(formic acid/methanol, 1 mL/1 L) and 90% mobile phase B
(formic acid/water, 1 mL/1 L), then increased linearly during
2 min until 50% A, which is maintained during 5 min, and then
back to 10% A during 5.5 min. Afterwards, 10% A was maintained
during 15 min in order to re-equilibrate the column before a new
injection. The LC set-up was connected to the electrospray source
for ionization (ESI) of the tandem mass spectrometry.
MS/MS. The AA identification was carried out on a Quattro
micro triple quadruple tandem mass spectrometer (Waters
Corporation). The electrospray source was used in positive
ionization mode for all analyses. Nitrogen and argon were used
as drying and collision gases, respectively. Source temperature was
fixed at 120uC and desolvatation temperature at 350uC. The cone
gas flow was fixed at 60 L/h, the desolvatation gas flow at 600 L/
h, the voltage multiplier at 650 V and the dwell time at 0.05 s. All
results were acquired with the MassLynx software version 4.0.
Specific MS, LC parameters (cone voltage, CV in V; collision
energy, CE in eV; retention time, RT in min) and internal
standards (AA*) used are given in Table 2.
Underivatized AA assay
The quantitative determination of underivatized AA was
achieved as reported by Piraud et al. [16]. All MS, LC parameters
and internal standards (AA*) used for each AA are given in Table 2.
Statistical Analysis
Results are expressed as the mean 6 standard error of the mean
(SEM). Statistical analysis of the differences between rat groups
Figure 2. Relative changes in activity, mRNA and protein expression of DDAH and arginase in the brain during the course of
infection in Trypanosoma brucei brucei (T. b. b.) infected rats. DDAH (A) and arginase (D) activities were measured in diencephalic
(hypothalamus/thalamus) biopsies. Results (mean value 6 SEM, n=6 per experimental day) were normalized with corresponding values measured in
control rats (n=6 per experimental day). Control values (100%), delineated by the dotted line, correspond to 269.6667.09 pmol/min/mg for DDAH
and to 26.3460.40 pmol/min/mg for arginase. Relative intensity of DDAH (B) and arginase (E) bands in western blot was calculated for each band and
the results expressed as a mean value for control and different experimental days (b-actin was used as an internal standard). The significant up-
regulation taking place for DDAH-2 transcription (C) is not observed for DDAH-1(C), ARG-1 or ARG-2 (F). The transcript levels for DDAH-1, DDAH-2, ARG-
1 and ARG-2 were estimated by real-time quantitative RT-PCR and normalized to 18S rRNA as endogenous control. The graphs represent the mean 6
SEM of 4 independent experiments (n=4 per experimental day). Statistics: ANOVA followed by post-hoc Fisher’s test (*p,0.05, **p,0.001 compared
to healthy rats). Abbreviations: DDAH, N
G,N
G-dimethylarginine dimethylaminohydrolase; DDAH-1, DDAH isoform 1; DDAH-2, DDAH isoform 2; Ctrl:
Control; ARG-1, arginase isoform 1; ARG-2, arginase isoform 2.
doi:10.1371/journal.pone.0016891.g002
DDAH and Arginase in Sleeping Sickness
PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e16891Figure 3. Immunostaining of DDAH-1 in the diencephalon of T. b. b.-infected rats. (A) Immunoreactivity of DDAH-1 observed in different
hypothalamic and thalamic structures: perifornical nucleus (PeF), magnocellular nucleus of the lateral hypothalamus (MCLH); lateral hypothalamic
area (LH); subincertal nucleus (SubI); zona incerta (ZI); reuniens thalamic nucleus (Re); central medial thalamic nucleus (CM); posterior thalamic nuclear
group (Po); ventral posterolateral (VPL) and posteromedial (VPM) thalamic nucleus; paracentral thalamic nucleus (PC); laterodorsal thalamic nucleus
(LD); and habenular nucleus (Hb). (B) Immunostaining of DDAH-1 (B-b, d) in kidney of healthy rats (control of specificity for anti-DDAH-1). For control
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(D5, D10, D16, D22) was performed by one-way analysis of
variance (ANOVA). When ANOVA was significant at p,0.05, a
post hoc Fisher’s least significant differences test was applied.
Results
Changes occurring in DDAH and arginase brain activity
Compared to healthy control rats, a significant increase in
DDAH activity was observed at D10 (164.81613.11%) and D16
(150.89610.01%) in diencephalic brain structures. Afterwards, at
D22 post-infection, the activity decreased towards control values
(Fig. 2A). No significant variation was observed in arginase activity
throughout the time course of the infection (Fig. 2D).
Brain expression of the two isoforms of DDAH
Accumulation of DDAH-2 protein isoform in the brain of
infected animals. Western blot analysis of hypothalamic and
thalamic tissue confirms the presence of DDAH-1 and DDAH-2
in these brain structures (Fig. 2B). In agreement with data on
DDAH activity, DDAH-2 protein levels increase in infected
animals at D10 and D16 post-infection (Fig. 2B). Therefore,
DDAH-1 did not differ between the two animal groups
throughout the time course of the infection (Fig. 2B).
Up-regulation of DDAH-2 transcription in the brain of
infected animals. Compared to healthy control animals, a
significant increase in mRNA transcripts of DDAH-2 was
observed in the diencephalon of infected animals at D10
(2.7660.64 fold) and D16 (1.8760.64 fold) (Fig. 2C). No change
was observed in the mRNA transcripts of DDAH-1.
Brain distribution of DDAH-1 and DDAH-2 protein
isoforms. DDAH-1 and, to a lesser extent, DDAH-2
immunoreactivities were observed in several brain areas (cortex,
hippocampus, amygdala) and notably in the hypothalamic and
thalamic groups of nuclei in healthy and infected rat (at D10 and
D16 post-infection) groups. For DDAH-1, a cytosolic
immunoreactivity was clearly identified among the interneurons of
the perifornical (PeF) nucleus and the magnocellular part of the
lateral hypothalamus.DDAH-1 immunoreactivity was alsoobserved
in the zona incerta (ZI), the habenular nuclei (Hb) and subincertal
(SubI), reuniens (Re), central medial (CM), posterior (Po), ventral
posterolateral (VPL), posteromedial (VPM), paracentral (PC), and
laterodorsal (LD) thalamic nuclei (Fig. 3A).
For DDAH-2, a cytosolic immunoreactivity was observed in the
neurons of submedial (Sub), mediodorsal (MD), ventral postero-
lateral (VPL), posteromedial (VPM), laterodorsal (LD), paracentral
(PC), posterior (Po), ventromedial (VM), ventrolateral (VL), and
centrolateral (CL) thalamic nuclei (Fig. 4A). Unlike DDAH-1 and
in agreement with western blot data (Fig. 2 B), our immunohis-
tochemical study revealed an increase in DDAH-2 protein
expression in infected rats in comparison to non-infected animals
(see the example of the ventral and posterior part of the thalamus
in Fig. 4B).
The specificity of anti-DDAH-1 and anti-DDAH-2 antibodies
used in the brain was verified by deploying the same immuno-
histochemical procedure in a rat kidney. DDAH was, indeed,
predominantly expressed in this organ (Fig. 3B). For DDAH-1, the
Immunostaining reactivity was exhibited in the cytoplasm of the
proximal convoluted tubular cells (Fig. 3B-b, d). For DDAH2, the
immunostaining was localized in the distal convoluted tubular cells
and the cortical and inner medullary collecting ducts (Fig. 4C-b,
d). A lack in staining was observed when either the anti-DDAH-1
or anti-DDAH-2 antibody were omitted in the immunohisto-
chemical procedure (Fig. 3B-a, c and 4C-a, c).
Morphometric analysis of DDAH-1 and DDAH-2
diencephalic expressing cells. In the ventral and posterior
parts of the thalamus, a Fisher’s post-hoc analysis revealed that, in
infected rats, the surface area of the soma and perimeter of cells
expressing DDAH-2 were significantly larger versus those
expressing DDAH-1 (Table 3). These two groups of cells
exhibited, however, a very close form factor (FF) (Table 3).
Considered as a whole, the analyses confirmed that DDAH-1
expressing cells belong to the interneuron cellular type.
Expression of the two arginase isoforms
Since both isoforms of arginase are expressed in the brain, we
tried to confirm the lack of differences in arginase activity in the
diencephalic brain structures (hypothalamus/thalamus) between
control and infected rats. In this respect, protein (western blot) and
mRNA (real-time RT-PCR) levels of arginase-1 and arginase-2
were analyzed in diencephalic brain structures during the time
course of the infection.
Western blot analysis of arginase-1 and arginase-2. In
agreement with data on arginase activity, arginase-1 and arginase-
2 protein levels did not differ between control and infected rats
throughout the time course of the infection (Fig. 2E).
Analysis of the mRNA of arginase-1 and arginase-2. As
expected from data on arginase activity and western blot analysis,
no significant changes were observed in diencephalic brain
structures for mRNA transcripts of arginase-1 and arginase-2
(Fig. 2F).
Changes occurring in the amino acids content
throughout the time course of the disease
In diencephalic brain structures, the main amino acids involved
in the metabolic pathways catalyzed by NOS, DDAH and
arginase were quantified from D5 to D22 after infection. In
infected rats, the variations of relative concentrations of L-arginine
and L-citrulline were in the same range. Compared to healthy
control rats, their concentrations decreased significantly at D10 (L-
arginine, 65.87617.07%, p,0.05; L-citrulline, 57.7665.03%,
p,0.001; n=6) and D16 (L-arginine, 82.3364.39%, p,0.05; L-
citrulline, 70.5268.17%, p,0.05; n=6). At D22 post infection,
the relative concentrations of the two amino acids returned to
control values (Fig. 5). No significant change was observed in the
relative concentrations of L-glutamate, L-glutamine (data not
shown), GABA, L-proline and L-ornithine in infected rats
throughout the investigation (Fig. 5). The presence of ADMA in
diencephalic brain structures was not detectable (data not shown).
Amino acids concentrations were also analyzed in the blood. In
infected rats, the relative concentrations of L-arginine and L-
citrulline decreased significantly at D5, D10 and D16 (Fig. 6). At
D22, the concentration of L-citrulline remained lower than control
values (73.87613.67%, p,0.05, n=6), while that of L-arginine
increased slightly above control values (128.76614.37%, p,0.05)
(Fig. 6). L-glutamate (Fig. 6) and L-glutamine (data not shown)
relative concentrations decreased significantly, from D10 (L-
glutamate, 66.44610.61%, p,0.05; L-glutamine, 60.06613.10%,
for the specificity of the secondary antibody, kidney sections were incubated without anti-DDAH-1 (B-a, c). Number of animals, n=3. The microscope
used was a Nikon Eclipse E400 equipped with Sony DXC-390P camera (objective: X20, X40). Abbreviations: DDAH-1, N
G,N
G-dimethylarginine
dimethylaminohydrolase isoform 1; see also figure 2.
doi:10.1371/journal.pone.0016891.g003
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glutamine, 33.25616.71%, p,0.001; n=6), and D22 (L-gluta-
mate, 43.24624.55%, p,0.001; L-glutamine, 18.9064.04%,
p=0.0001; n=6). Plasma relative concentration of ADMA
increased significantly throughout the time course of the illness,
from D10 (155.96630.44%, p,0.05, n=6) to D16
(182.51637.99%, p,0.001, n=6), and D22 (207.91648.58%,
p,0.001, n=6), (Fig. 6).
Discussion
First of all, we must emphasize the adequacy of the T. b. brucei-
infected rat model in mimicking closely the two-stage disease in
human T. b. gambiense infection. As previously reported in our rat
model, the initiation of the neurological stage of the disease is
characterized by a marked decrease in body weight gain and the
presence of trypanosomes in the CSF 10 days post-infection [2].
The neurological stage is also marked by an increase in cerebral
iNOS activity, leading to an overproduction of NO in the brain.
By use of double labeling, we have also shown that the iNOS
immunoreactivity is located in glial elements (microglia and
astrocytes) as well as in neurons, especially in brain structures
involved in the sleep/wake regulation (lateral and posterior part of
the hypothalamus, perifornical area) [2]. The present investigation
was designed to study the molecular changes occurring in arginase
and DDAH in the brain at the key stages of the HAT infection.
We suggest that DDAH most likely contributes to the regulation of
iNOS activity in the brain, whereas arginase has a slight effect, if
any, contrary to its role in the periphery.
Arginase pathway
Concerning the arginase pathway, experimental data obtained
in the brain indicate that, throughout the time course of the
disease, no significant changes occurred in the total activity of
arginase in the protein or in the mRNA levels of the two isoforms
of the enzyme (arginase-1 and -2). This is also evident from the
absence of any significant changes in the concentration of the
major amino acids involved in the arginase pathway, such as L-
ornithine, L-proline, L-glutamate, L-glutamine, and L-GABA.
Since the arginase activity remained unchanged throughout the
course of the experimental illness, the decrease in L-arginine
content, observed at D10 and D16 post-infection, may be due to
the utilization of the substrate through the iNOS pathway [2].
Nevertheless, we cannot exclude a possible increase in the
arginosuccinate synthetase (ASS) and arginosuccinate lyase (ASL)
activities which would favor an increase in the concentration of L-
arginine by recycling L-citrulline to L-arginine. Such a mechanism
has been reported in rats subjected to brain excitotoxicity
mediated by kainic acid. An increase in the production of NO
in parallel to ASS and ASL activities takes place in the cerebral
cortex, cerebellum and brain stem, while the arginase activity
remains unchanged [18]. These mechanisms remain to be further
investigated.
In the present approach, we did not examine the changes
occurring in arginase activity in the periphery, as such changes
have already been addressed [4,11]. In this respect, we suggested
[2] that arginase activity changes occurring in the periphery may
reflect the strategy developed by trypanosomes to invade the host
and insure their own survival and development through (i)
enhancement of arginase activity mediating the synthesis of
polyamines necessary to trypanosome growth, and (ii) limitation
of trypanocidal properties carried out by the decrease in NO
production. Arginase appears therefore to be a critical regulator of
NO synthesis, through a competition with iNOS for L-arginine
[19]. In this respect, a significant decrease in plasma L-arginine
concentration was observed in our infected rats. Such a change
was also reported in T. b. brucei-infected mice [4] and T. b.
gambiense-infected voles [20]. A large proportion of the L-arginine
in the blood might be metabolized by arginase since iNOS is
inhibited during the time course of the infection [2], reducing NO
production and, consequently, trypanocidal pressure. In support of
this interpretation, L-arginine supplementation in T. b. brucei-
infected mice restores both NO production and NO trypanocidal
activity [4,11]. Furthermore, in the periphery, the arginase genes
are up-regulated throughout the course of the infection. Arginase-
1 and, to a lower extent, arginase-2 genes can be induced directly
by the trypanosomes. Moreover, interleukin-4 (IL-4), IL-10 and
Transforming Growth Factor-b (TGF-b), which are potent
arginase inducers, are enhanced in experimental trypanosomiasis
[21]. Alternatively, arginase activation can also result from a direct
interaction between trypanosome products, such as the trypano-
some-derived lymphocyte-triggering factor (TLTF), and T lym-
phocytes [22]. In any case, arginase activation enhances the
production of polyamines that are essential for the synthesis of the
trypanothione, a compound necessary for growth and survival of
trypanosomes (Fig. 1). Trypanothione synthesis from glutathione
and spermidine [23] may account for the significant decrease in
glutamate and glutamine concentration observed at the peripheral
level in our infected rats.
In the brain, the situation does not appear to be favorable for
trypanosome multiplication and spread, since trypanocidal NO
Figure 4. Immunostaining of DDAH-2 in the diencephalon of T. b. b.-infected rats. (A) Immunohistochemistry for DDAH-2 observed in
different thalamic structures: submedius thalamic nucleus (Sub); mediodorsal thalamic nucleus (MD); ventral posterolateral and posteromedial
thalamic nucleus (VPL, VPM); laterodorsal thalamic nucleus (LD); paracentral thalamic nucleus (PC); posterior thalamic nuclear group (Po);
ventromedial thalamic nucleus (VM); ventrolateral thalamic nucleus (VL); centrolateral thalamic nucleus (CL). (B) Comparison of the DDAH-2 protein
expression shown by immunohistochemistry in the ventral posterior nucleus of the thalamus between infected animals and control healthy rats. (C)
Immunostaining of DDAH-2 (B-b, d) in the kidney of healthy rats (control of specificity of anti-DDAH-2). The specificity of the secondary antibody was
verified by incubating kidney sections without anti-DDAH-2 (B-a, c). Number of animals, n=3. The microscope used was a Nikon Eclipse E400
equipped with Sony DXC-390P camera (objective: X20, X40). Abbreviations: DDAH-2, N
G,N
G-dimethylarginine dimethylaminohydrolase isoform 2; see
also figure 2.
doi:10.1371/journal.pone.0016891.g004
Table 3. Morphometric parameters for differentiation of
DDAH-1 and DDAH-2 cell groups in Trypanosoma brucei
brucei-infected Wistar rats.
Soma area
(mm
2)
Soma perimeter
(mm) Soma FF
DDAH-1 (n=134) 33.3360.61 26.0160.36 0.6360.01
DDAH-2 (n=134) 125.5163.35 52.8060.94 0,5760,09
P value* ,0.0001 ,0.0001 N.S**
*The values given represent the mean 6 standard deviation; a Fisher’s post-hoc
analysis was achieved.
FF: The form factor.
**N.S: Non significant.
doi:10.1371/journal.pone.0016891.t003
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remain stable. These mechanisms may act as additive protective
elements for the brain, although trypanosomes will still be able to
enter the central nervous system. The parasites pass through the
blood-brain barrier (BBB) across or between the endothelial cells
and the vessel basement membranes [24]. The trypanosomes are
present in cerebrospinal fluid (CSF), especially in such areas where
the BBB is weak, i.e., at the level of the circumventricular organ
and around the ventricular cavities [2,25,26]. Due to the large
concentration of NO in the extracellular space of the brain
parenchyma [2], it is likely that trypanosomes cannot penetrate
easily into deeper structures. Furthermore, trypanosomes present
in the brain parenchyma are described as being damaged [27],
underlining potential difficulties to survive in such conditions.
Intracellular localization of African trypanosomes may also protect
the parasites against the trypanocidal properties of NO [28,29].
Due to the lack of changes observed in the arginase activity during
the course of the infection, the energy necessary for trypanosome
growth may be supplied by the high rate of the brain metabolism
[30].
3462 mM for L-arginine; 1061 mM for L-citrulline; 892636 mM for L-glutamate; 796680 mM for L-GABA; 1661 mM for L-proline and 560.4 mM for L-
ornithine. Concentration of ADMA was undetectable. Statistics: ANOVA followed by post-hoc Fisher’s test (*p,0.05, **p,0.001 compared to healthy
rats); n=6 animals in each group at the different times post-infection: D5, D10, D16 and D22. Abbreviations: GABA, c-aminobutyric acid; see also
figure 2.
doi:10.1371/journal.pone.0016891.g005
Figure 6. Relative changes in the content of amino acid in blood during the course of infection in T. b. b.-infected rats. The changes in
the concentration of amino acids (mean value 6 SEM) in the blood of infected rats were normalized with the corresponding values obtained in
healthy control animals. 100% of the control values (delineated by the dotted line) correspond to: 11063 mM for L-arginine; 10064 mM for L-
citrulline; 9564 mM for L-glutamate and 0.9660.1 mM for ADMA. Statistics: ANOVA followed by post-hoc Fisher’s test (*p,0.05, **p,0.001,
***p,0.0001 compared to healthy rats); n=6 animals in each group at the different times post-infection: D5, D10, D16 and D22. Abbreviations:
ADMA, asymmetric dimethylarginine; see also figure 2.
doi:10.1371/journal.pone.0016891.g006
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Similar to our observations on the arginase pathway, the
DDAH/ADMA pathway may also play a key role in the
regulation of NO production since ADMA acts as a potent iNOS
inhibitor [31]. Indeed, we demonstrate that the cerebral activity of
DDAH, mRNA and protein expression increase significantly in
the later stage of the disease (at D10 and D16 after infection)
concomitant with the activation of iNOS (activity and protein
expression) and the enhancement of NO production [2]. The tight
correlation existing between these events supports the hypothesis
Figure 7. Schematic representation of the enzymatic pathways involved in the control of trypanosome entry into the brain during
the later stage of the disease. In the periphery (blood), the arginase is strongly expressed in the activated macrophages and competes with iNOS
for a common substrate, L-arginine. This phenomenon, under control of cytokines, leads to a decrease in iNOS activity and consequently in the
production of NO, a gaseous messenger possessing trypanocidal properties. Such a mechanism, favoring the growth and multiplication of the
parasites, is strengthened by the accumulation of the endogenous inhibitor of iNOS, ADMA, as observed in the blood. An opposite mechanism is
observed in the brain since the activity of iNOS increases in the three cell types: neurons, microglia and astrocytes. DDAH-2 is over expressed in
neurons, likely by decreasing the ADMA pool, and may enhance iNOS activity and, consequently, NO production. Concomitantly, the activity and
expression of the arginase remain unchanged. Abbreviations: NO, nitric oxide; iNOS, inducible nitric oxide synthase; ADMA, asymmetric
dimethylarginine; DDAH, N
G,N
G-dimethylarginine dimethylaminohydrolase. Small arrows indicate an increase in the given product when pointing
upwards and a decrease when pointing downwards. Hyphen is used to indicate that the amount in the given molecule is stable.
doi:10.1371/journal.pone.0016891.g007
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(particularly at D16) in the brain during the invasion by
trypanosomes. In line with this view, it was suggested that, in
inflammatory conditions (such as in the present case), the
activation of DDAH may contribute to reduce the level of ADMA
[32].There are also reports indicating that ADMA concentration is
significantly lower (248%) in the CSF of patients suffering of
Alzheimer’s disease or in pathological aging with cognitive
impairment [33]. Trypanosomiasis might thus also contain
insidious neurodegenerative processes and therefore represent a
model of neurodegenerative diseases.
In our experimental model, the cerebral increase in DDAH
activity is mainly dependent on the DDAH-2 isoform which is
transcriptionally regulated, a specific increase in DDAH-2 mRNA
occurring throughout the infection. The DDAH-2 gene is located
on chromosome 6 (6p21.3) in a region containing various genes
involved in inflammatory processes linked with the autoimmune
disease susceptibility [9]. This localization and the wide expression
of DDAH-2 in immune cells suggest that the DDAH-2 gene may
represent a potential disease-susceptibility gene. In this sense, it has
been reported that inflammatory cytokines such as IL-1b are
capable of simulating simultaneously iNOS and DDAH in
vascular smooth muscle cells [34]. This effect is accompanied by
an increase in NO metabolites and a decrease in ADMA content
in culture media. A chronic overexpression of proinflammatory
cytokines (IL-1, TNF-a) and IFN-c in the brains of T. b. -infected
rats, might be responsible for the iNOS and DDAH-2 up-
regulation, leading to a reduction of trypanosome proliferation,
neuroinflammation and neurodegeneration [35].
In diencephalic brain structures, DDAH-2 immunoreactivity
was primarily observed in neurons. It was enhanced in infected
rats as compared with healthy animals. Contrary to DDAH-2, no
significant change was noticed with DDAH-1 immunoreactivity
between infected and non-infected animals. It should be noted that
DDAH-1 immunoreactivity is located in interneurons which
express also nNOS [36,37], an enzyme that remains unchanged
throughout the T. b. b. infection process [2].
Recently, Gow et al. [38] reported that NO may S-nitrosylate a
distinct subset of cellular proteins, DDAH being one of them. The
cellular proteins may be regulated by S-nitrosylation through the
NO derived from iNOS [10]. Under certain conditions, when NO
increases, the S-nitrosylation of DDAH decreases its activity. This
mechanism would lead to an accumulation of ADMA and
consequently to the inhibition of the iNOS. The S-nitrosylation
of DDAH provides thus a potential feedback mechanism for the
regulation of NO production. This mechanism could explain why,
in our experimental model of HAT, the activities of both iNOS
and DDAH return simultaneously to the control level at D22 after
infection. Such an effect may reflect the pre-mortem situation of our
infected animals at that time of the infection course. In such
extreme conditions, anti-inflammatory processes may be triggered
to protect the brain as reported in autoimmune encephalitis [39].
Peripheral ADMA concentration was elevated in our T. b.
brucei-infected rats. These changes coincide with the entry into the
second stage of the disease and correlate with the degree of the
infection. The mechanism responsible for the increase in the
ADMA level was not specifically investigated in this study. It may
be explained, at least partly, by the existence of a decrease in the
concentration of L-citrulline which occurs in parallel with the
ADMA increase. It is also known that ADMA accumulation is
associated with an endothelial dysfunction [40]. Recent in vitro and
in vivo studies indicate that an enhanced ADMA synthesis coincides
with an increased activity of the immune pathways, such as in HIV
infected patients [41,42]. In this respect, ADMA can be produced
by the endothelial cells and the activated mononuclear blood cells
[42]. The latter cellular elements release simultaneously Th1-type
cytokine, interferon-c (IFN-c, an important NOS inducer) and
ADMA [41]. It has also been reported that even modest changes
in the ADMA level can have significant effects on NO synthesis
[31]. In our previous studies [2], we reported that circulating NO
concentration decreases significantly from D10 post-infection (in
correlation with illness progression) and that this decrease is likely
to depend on an impaired iNOS activity in macrophages. We
suggest that ADMA may also contribute to the inhibition of NO
synthesis in the periphery.
Conclusion. In the T. b. brucei-infected rat model of human
African trypanosomiasis, we demonstrated that the activity of
cerebral arginase remains constant throughout the time course of
the infection. Simultaneously, DDAH-2 isoform increased,
contributing to an overproduction of NO, undoubtedly through
a reduction of the ADMA level, a known iNOS inhibitor. These
changes differed from those reported in the periphery in the same
animal model (Fig. 7). They may constitute an additive protection
against the trypanosomes that have entered the central nervous
system, through the increase in the trypanocidal pressure carried
by NO, while the arginase activity necessary for trypanosomes
growth remained unchanged. The involvement of NO
overproduction in the pathophysiology of the neurological stage
of trypanosomiasis might also be considered.
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